Relationship Between Growth Differentiation Factor-15 Levels and Micro-Atrial Fibrillation
Methods: Ninety patients who underwent 24-hour Holter monitoring due to palpitations were enrolled. Forty-five patients with micro-AF and 45 controls without supraventricular tachyarrhythmia were compared. Serum GDF-15 levels and clinical characteristics were analyzed using standard statistical methods, including logistic regression analysis and Receiver Operating Characteristic (ROC) curve analyses.
Results: The groups were similar in age, sex, and comorbidities. Prior stroke was significantly more frequent in the micro-AF group (28.8% vs. 6.7%, P<0.001). Mean serum GDF-15 levels were significantly higher in patients with micro-AF than in controls (544.2±322.5 vs. 344±138.8 pg/mL, P<0.001). Logistic regression revealed that GDF-15 was associated with stroke risk in univariate analysis but not independently in multivariate analysis.
Conclusions: Elevated GDF-15 levels in individuals with micro-AF suggest an underlying inflammatory or structural atrial substrate, supporting its potential role as a biomarker for early arrhythmia detection and assessment of thromboembolic risk. Larger, prospective studies are warranted to clarify the prognostic significance of GDF-15 in micro-AF.
1. Cheng S, He J, Han Y, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021. Europace. 2024;26(7):euae195. doi: 10.1093/europace/euae195.
2. Swiryn S, Orlov MV, Benditt DG, et al.; RATE Registry Investigators. Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. Circulation. 2016;134(16):1130-1140. doi: 10.1161/CIRCULATIONAHA.115.020252.
3. Fredriksson T, Gudmundsdottir KK, Frykman V, et al. Brief episodes of rapid irregular atrial activity (micro-AF) are a risk marker for atrial fibrillation: a prospective cohort study. BMC Cardiovasc Disord. 2020;20(1):167. doi: 10.1186/s12872-020-01453-w.
4. Meng L, Tsiaousis G, He J, et al. Excessive Supraventricular Ectopic Activity and Adverse Cardiovascular Outcomes: a Systematic Review and Meta-analysis. Curr Atheroscler Rep. 2020;22(4):14. doi: 10.1007/s11883-020-0832-4.
5. Chen LY, Chung MK, Allen La, et al. American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association. Circulation. 2018;137(20):e623-e644. doi: 10.1161/CIR.0000000000000568.
6. Turakhia MP, Shafrin J, Bognar K, et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS One. 2018;13(4):e0195088. doi: 10.1371/journal.pone.0195088.
7. Aydın C. [Possible predictors of stroke in patients with atrial microfibrillation]. Kardiologiia. 2023;63(5):40-46. doi: 10.18087/cardio.2023.5.n2158. [Article in Russian]
8. Ari H, Ari S, Akkaya M, et al. Predictive value of atrial electromechanical delay for atrial fibrillation recurrence. Cardiol J. 2013;20(6):639-647. doi: 10.5603/CJ.2013.0164.
9. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115(8):962-971. doi: 10.1161/CIRCULATIONAHA.106.650846.
10. Hijazi Z, Lindbäck J, Alexander JH, et al.; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582-1590. doi: 10.1093/eurheartj/ehw054.
11. Hijazi Z, Oldgren J, Wallentin L, et al. Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". Circulation. 2013;127(2):e278-279. doi: 10.1161/circulationaha.112.133546.
12. Meems LMG, Artola Arita V, Velt M, et al. Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study. Int J Cardiol Heart Vasc. 2022;39:100987. doi: 10.1016/j.ijcha.2022.100987.
13. Aulin J, Hijazi Z, Lindbäck J, et al.; ARISTOTLE Investigators. Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. Am Heart J. 2022;251:13-24. doi: 10.1016/j.ahj.2022.03.009.
14. Wei Y, Cui M, Liu S, Yu H, Gao W, Li L. [Different levels and clinical significance of growth differentiation factor-15 in patients with atrial fibrillation]. Beijing Da Xue Xue Bao Yi Xue Ban. 2024;56(4):715-721. doi: 10.19723/j.issn.1671-167X.2024.04.027. [Article in Chinese]
15. May BM, Pimentel M, Zimerman LI, Rohde LE. GDF-15 as a Biomarker in Cardiovascular Disease. Arq Bras Cardiol. 2021;116(3):494-500. doi: 10.36660/abc.20200426.
16. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98(3):351-360. doi: 10.1161/01.RES.0000202805.73038.48.
17. Walter J, Nestelberger T, Boeddinghaus J, et al.; APACE investigators. Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarction. Int J Cardiol. 2019;292:241-245. doi: 10.1016/j.ijcard.2019.04.088.
Copyright (c) 2025 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Article Information
- Article Type Research Article
- Submitted February 21, 2026
- Published March 14, 2026
- Issue 2026: Online First
- Section Research Article
